DNA Repair–Based Mechanisms of Platinum Resistance in Epithelial Ovarian Cancer: From Bench to Bedside

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Ovarian Cancer

• Publication date

  2010-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3816/COC.2010.N.005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis.

  2023cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG).

  2009cited by this paper
• BRCA1 and implications for response to chemotherapy in ovarian cancer.

  2009cited by this paper
• Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.

  2008cited by this paper
• Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

  2008cited by this paper
• DNA repair pathways as targets for cancer therapy

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• Second-line therapy for ovarian cancer.

  2008cited by this paper
• BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

  2007cited by this paper
• ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.

  2007cited by this paper
• ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

  2007cited by this paper
• Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

  2007cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Mismatch repair and treatment resistance in ovarian cancer

  2006cited by this paper
• DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

  2006cited by this paper
• Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma

  2005cited by this paper
• BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

  2005cited by this paper
• 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• CpG island methylation of DNA damage response genes in advanced ovarian cancer.

  2005cited by this paper
• The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

  2004cited by this paper
• Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

  2004cited by this paper
• Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene

  2004cited by this paper
• Role of DNA mismatch repair defects in the pathogenesis of human cancer.

  2003cited by this paper
• BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

  2003cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.

  2003cited by this paper
• A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

  2003cited by this paper
• Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

  2002cited by this paper
• Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.

  2002cited by this paper
• Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

  2001cited by this paper
• New complexities for BRCA1 and BRCA2.

  2001cited by this paper
• A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer

  2001cited by this paper
• Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer.

  2001cited by this paper
• Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

  2000cited by this paper
• Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Action of DNA repair endonuclease ERCC1/XPF in living cells.

  1999cited by this paper
• Advanced epithelial ovarian cancer: 1998 consensus statements.

  1999cited by this paper
• BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

  1998cited by this paper
• Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

  1997cited by this paper
• Second‐line chemotherapy for recurrent carcinoma of the ovary

  1993cited by this paper
• Advanced epithelial ovarian cancer: 1998 consensus statements.

  1993cited by this paper
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

  1991cited by this paper
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

  1990cited by this paper
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

  1989cited by this paper
• Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

  year unknowncited by this paper

• Tripeptide-Stabilized Oil-in-Water Nanoemulsion of an Oleic Acids-Platinum(II) Conjugate as an Anticancer Nanomedicine.

  2018cites this paper
• MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2

  2016cites this paper
• Investigation of the impact of HNPCC gene deficiency on outcome in epithelial ovarian cancer

  2015cites this paper
• Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?

  2014cites this paper
• Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.

  2014cites this paper
• DNA-repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival

  2011cites this paper